Kura Oncology NASDAQ: KURA reported $5.8 million in first-quarter net product revenue from KOMZIFTI, its first commercial product, and said the launch is showing early signs of physician uptake, broad payer coverage and use in combination regimens, according to management’s earnings call for the first quarter of 2026.President and Chief Executive Officer Dr. Troy Wilson described the company as being “at an inflection point,” citing the commercial launch, phase III programs that he said are ahead of plan an ...